Share Price and Basic Stock Data
Last Updated: December 16, 2025, 4:32 pm
| PEG Ratio | 4.23 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Max Healthcare Institute Ltd has established itself as a significant player in the Indian healthcare sector, catering to the growing demand for quality medical services. The company reported total sales of ₹4,563 Cr for FY 2023, reflecting a remarkable increase from ₹3,931 Cr in FY 2022. This upward trajectory continued into FY 2024, with revenues expected to rise to ₹5,406 Cr. The trend is promising, with quarterly sales consistently climbing from ₹1,067 Cr in June 2022 to ₹1,363 Cr by September 2023. This growth indicates a robust demand for healthcare services, likely driven by an expanding patient base and increasing healthcare awareness among Indians. However, the company’s performance is not without challenges; the healthcare industry is inherently competitive and sensitive to regulatory changes, which could impact future growth. Overall, Max Healthcare’s revenue trends present a solid narrative of resilience and expansion, positioning it well in the healthcare landscape.
Profitability and Efficiency Metrics
Max Healthcare’s profitability metrics are noteworthy, showcasing its ability to manage costs while expanding operations. The reported operating profit margin (OPM) stood at 27% in FY 2025, slightly lower than the previous year’s 28%. This is indicative of efficient cost management, despite rising operational expenses, which increased to ₹5,180 Cr in FY 2025 from ₹3,914 Cr in FY 2024. Net profit for FY 2025 was recorded at ₹1,076 Cr, translating to an earnings per share (EPS) of ₹11.07. While the P/E ratio at 74.5 suggests that the stock may be overvalued compared to sector norms, it underscores the market’s confidence in the company’s growth potential. The interest coverage ratio of 12.15x indicates a comfortable ability to meet interest obligations, further reinforcing the firm’s financial health. However, the declining net profit margin from 24.18% in FY 2023 to 15.30% in FY 2025 raises questions about long-term sustainability, highlighting the need for vigilant cost management.
Balance Sheet Strength and Financial Ratios
Max Healthcare’s balance sheet reflects a growing concern over financial leverage, as evidenced by total borrowings rising sharply to ₹3,010 Cr in FY 2025, up from ₹1,299 Cr in FY 2024. While the company has substantial reserves of ₹8,409 Cr, the debt-to-equity ratio of 0.26x points to a relatively conservative financial structure. The return on equity (ROE) of 11.46% and return on capital employed (ROCE) of 12.27% suggest that the company is effectively utilizing its capital to generate profits. However, the current ratio of 0.87 indicates potential liquidity issues, as the firm may face challenges in covering short-term obligations. The asset turnover ratio at 0.51% is also a cause for concern, suggesting that the company may not be using its assets as efficiently as possible to generate revenue. Overall, while Max Healthcare shows strength in its reserves and profitability, the rising debt levels and liquidity concerns warrant a closer examination.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Max Healthcare gives insight into its investor confidence and market dynamics. Promoters hold a stable 23.74% stake, which reflects a commitment to the company. Foreign Institutional Investors (FIIs) have a significant presence, holding 51.80% of the shares, suggesting strong international interest in the firm’s growth prospects. Domestic Institutional Investors (DIIs) hold 20.03%, indicating a healthy level of domestic institutional backing. However, the public shareholding remains relatively low at 4.43%, which could be a point of concern for retail investors looking for liquidity. The number of shareholders has risen from 1,11,701 in December 2022 to 1,80,891 by June 2025, signaling growing retail interest. This mix of institutional and retail investors could provide a buffer against market volatility, although the concentrated ownership by FIIs may also lead to fluctuations in stock price based on global market trends.
Outlook, Risks, and Final Insight
Looking ahead, Max Healthcare’s trajectory appears promising, but not without its risks. The healthcare sector’s growth is subject to various factors, including regulatory challenges, rising operational costs, and competition from both public and private players. While the company’s revenue growth and profitability metrics are strong, the rising debt levels and liquidity concerns could pose risks to its financial stability in the long term. Investors should also consider the impact of economic fluctuations on healthcare spending, as discretionary spending can be affected during downturns. In conclusion, while Max Healthcare presents a compelling story of growth and resilience, potential investors must weigh these strengths against the backdrop of operational risks and financial health. A cautious approach, focusing on the company’s ability to manage its debt and maintain profitability, will be essential for making informed investment decisions in this evolving sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 41.9 Cr. | 125 | 195/120 | 8.56 | 117 | 2.80 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 22.6 Cr. | 21.5 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 9.19 Cr. | 8.89 | 20.8/8.28 | 102 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 116 Cr. | 61.6 | 98.7/55.2 | 25.5 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.2 Cr. | 3.74 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,193.00 Cr | 755.94 | 94.42 | 99.39 | 0.32% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,067 | 1,137 | 1,142 | 1,215 | 1,285 | 1,363 | 1,335 | 1,423 | 1,543 | 1,707 | 1,868 | 1,910 | 2,028 |
| Expenses | 802 | 818 | 828 | 874 | 948 | 976 | 949 | 1,041 | 1,156 | 1,257 | 1,369 | 1,398 | 1,505 |
| Operating Profit | 265 | 319 | 314 | 340 | 337 | 387 | 386 | 382 | 387 | 451 | 499 | 512 | 523 |
| OPM % | 25% | 28% | 28% | 28% | 26% | 28% | 29% | 27% | 25% | 26% | 27% | 27% | 26% |
| Other Income | 31 | 26 | 45 | 40 | 41 | 45 | 46 | 45 | 35 | 41 | -40 | 47 | 37 |
| Interest | 22 | 22 | 20 | 20 | 19 | 9 | 11 | 21 | 24 | 34 | 52 | 55 | 55 |
| Depreciation | 57 | 58 | 57 | 60 | 56 | 58 | 61 | 70 | 77 | 84 | 98 | 101 | 104 |
| Profit before tax | 216 | 265 | 281 | 301 | 303 | 366 | 360 | 336 | 321 | 374 | 309 | 402 | 400 |
| Tax % | 20% | -72% | 21% | 17% | 21% | 24% | 20% | 25% | 26% | 25% | 23% | 21% | 23% |
| Net Profit | 173 | 457 | 222 | 251 | 240 | 277 | 289 | 252 | 236 | 282 | 239 | 319 | 308 |
| EPS in Rs | 1.78 | 4.72 | 2.29 | 2.58 | 2.47 | 2.85 | 2.98 | 2.59 | 2.43 | 2.90 | 2.46 | 3.28 | 3.17 |
Last Updated: August 20, 2025, 7:05 am
Below is a detailed analysis of the quarterly data for Max Healthcare Institute Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2,028.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,910.00 Cr. (Mar 2025) to 2,028.00 Cr., marking an increase of 118.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,505.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,398.00 Cr. (Mar 2025) to 1,505.00 Cr., marking an increase of 107.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 523.00 Cr.. The value appears strong and on an upward trend. It has increased from 512.00 Cr. (Mar 2025) to 523.00 Cr., marking an increase of 11.00 Cr..
- For OPM %, as of Jun 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Mar 2025) to 26.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 47.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 10.00 Cr..
- For Interest, as of Jun 2025, the value is 55.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 55.00 Cr..
- For Depreciation, as of Jun 2025, the value is 104.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 400.00 Cr.. The value appears to be declining and may need further review. It has decreased from 402.00 Cr. (Mar 2025) to 400.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Mar 2025) to 23.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 308.00 Cr.. The value appears to be declining and may need further review. It has decreased from 319.00 Cr. (Mar 2025) to 308.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.17. The value appears to be declining and may need further review. It has decreased from 3.28 (Mar 2025) to 3.17, marking a decrease of 0.11.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:59 am
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,608 | 1,729 | 1,691 | 1,059 | 2,505 | 3,931 | 4,563 | 5,406 | 7,028 | 7,941 |
| Expenses | 1,467 | 1,616 | 1,535 | 965 | 2,101 | 2,986 | 3,322 | 3,914 | 5,180 | 5,832 |
| Operating Profit | 141 | 113 | 156 | 94 | 404 | 946 | 1,241 | 1,492 | 1,849 | 2,109 |
| OPM % | 9% | 7% | 9% | 9% | 16% | 24% | 27% | 28% | 26% | 27% |
| Other Income | 59 | 65 | 56 | 48 | -119 | 115 | 139 | 178 | 82 | 76 |
| Interest | 100 | 99 | 101 | 83 | 179 | 101 | 84 | 60 | 165 | 216 |
| Depreciation | 96 | 94 | 103 | 46 | 174 | 221 | 232 | 245 | 359 | 411 |
| Profit before tax | 5 | -15 | 8 | 13 | -69 | 739 | 1,064 | 1,365 | 1,406 | 1,558 |
| Tax % | -236% | 65% | 102% | -1% | 67% | 18% | -4% | 23% | 24% | |
| Net Profit | 16 | -25 | -0 | 59 | -138 | 605 | 1,104 | 1,058 | 1,076 | 1,357 |
| EPS in Rs | 0.29 | -0.47 | -0.06 | 1.10 | -1.42 | 6.24 | 11.37 | 10.88 | 11.07 | 13.96 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 9% | 14% | 14% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -256.25% | 100.00% | -333.90% | 538.41% | 82.48% | -4.17% | 1.70% |
| Change in YoY Net Profit Growth (%) | 0.00% | 356.25% | -433.90% | 872.30% | -455.93% | -86.65% | 5.87% |
Max Healthcare Institute Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 21% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 64% |
| 3 Years: | 23% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 59% |
| 3 Years: | 45% |
| 1 Year: | 32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 14% |
| Last Year: | 13% |
Last Updated: Unknown
Balance Sheet
Last Updated: December 10, 2025, 3:04 am
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 537 | 537 | 537 | 537 | 966 | 970 | 971 | 972 | 972 | 972 |
| Reserves | 655 | 627 | 426 | 2,016 | 4,673 | 5,313 | 6,439 | 7,436 | 8,409 | 9,080 |
| Borrowings | 874 | 981 | 1,003 | 875 | 1,101 | 913 | 689 | 1,299 | 3,010 | 3,275 |
| Other Liabilities | 1,080 | 1,157 | 1,389 | 546 | 1,803 | 1,993 | 2,003 | 2,293 | 2,795 | 2,954 |
| Total Liabilities | 3,146 | 3,302 | 3,355 | 3,974 | 8,543 | 9,189 | 10,102 | 12,000 | 15,186 | 16,281 |
| Fixed Assets | 2,244 | 2,227 | 2,192 | 851 | 6,536 | 7,018 | 7,039 | 8,784 | 11,502 | 11,826 |
| CWIP | 46 | 38 | 87 | 28 | 27 | 151 | 252 | 553 | 901 | 1,226 |
| Investments | 0 | 0 | 1 | 2,182 | 1 | 1 | 1 | 2 | 3 | 5 |
| Other Assets | 856 | 1,036 | 1,075 | 913 | 1,980 | 2,020 | 2,810 | 2,661 | 2,781 | 3,223 |
| Total Assets | 3,146 | 3,302 | 3,355 | 3,974 | 8,543 | 9,189 | 10,102 | 12,000 | 15,186 | 16,281 |
Below is a detailed analysis of the balance sheet data for Max Healthcare Institute Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 972.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 972.00 Cr..
- For Reserves, as of Sep 2025, the value is 9,080.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,409.00 Cr. (Mar 2025) to 9,080.00 Cr., marking an increase of 671.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,275.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3,010.00 Cr. (Mar 2025) to 3,275.00 Cr., marking an increase of 265.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,954.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,795.00 Cr. (Mar 2025) to 2,954.00 Cr., marking an increase of 159.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 16,281.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15,186.00 Cr. (Mar 2025) to 16,281.00 Cr., marking an increase of 1,095.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11,826.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,502.00 Cr. (Mar 2025) to 11,826.00 Cr., marking an increase of 324.00 Cr..
- For CWIP, as of Sep 2025, the value is 1,226.00 Cr.. The value appears strong and on an upward trend. It has increased from 901.00 Cr. (Mar 2025) to 1,226.00 Cr., marking an increase of 325.00 Cr..
- For Investments, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,223.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,781.00 Cr. (Mar 2025) to 3,223.00 Cr., marking an increase of 442.00 Cr..
- For Total Assets, as of Sep 2025, the value is 16,281.00 Cr.. The value appears strong and on an upward trend. It has increased from 15,186.00 Cr. (Mar 2025) to 16,281.00 Cr., marking an increase of 1,095.00 Cr..
Notably, the Reserves (9,080.00 Cr.) exceed the Borrowings (3,275.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -733.00 | -868.00 | 155.00 | -781.00 | 403.00 | 33.00 | -688.00 | 0.00 | -2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53 | 59 | 78 | 80 | 53 | 36 | 27 | 31 | 36 |
| Inventory Days | 20 | 24 | 26 | 40 | 34 | 24 | 30 | 26 | 26 |
| Days Payable | 184 | 227 | 292 | 273 | 274 | 174 | 215 | 207 | 200 |
| Cash Conversion Cycle | -111 | -144 | -188 | -153 | -187 | -114 | -158 | -149 | -138 |
| Working Capital Days | -12 | -24 | -152 | -191 | -44 | -24 | -46 | -43 | -47 |
| ROCE % | 4% | 6% | 11% | 7% | 12% | 15% | 16% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Equity Hybrid Fund | 7,000,000 | 0.98 | 813.96 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 6,300,000 | 1.74 | 732.56 | N/A | N/A | N/A |
| Kotak Midcap Fund | 5,338,730 | 1.03 | 620.79 | N/A | N/A | N/A |
| Motilal Oswal Midcap Fund | 5,270,000 | 1.61 | 612.8 | N/A | N/A | N/A |
| Invesco India Large & Mid Cap Fund | 4,598,460 | 5.68 | 534.71 | 4,225,932 | 2025-12-14 20:43:52 | 8.82% |
| Canara Robeco Large and Mid Cap Fund | 4,239,096 | 1.88 | 492.92 | N/A | N/A | N/A |
| HDFC Large Cap Fund | 3,798,316 | 1.09 | 441.67 | 2,647,215 | 2025-12-15 06:13:35 | 43.48% |
| PGIM India Midcap Fund | 2,981,264 | 3.01 | 346.66 | 3,526,055 | 2025-12-14 03:33:18 | -15.45% |
| Axis ELSS Tax Saver Fund | 2,447,613 | 0.81 | 284.61 | N/A | N/A | N/A |
| Edelweiss Mid Cap Fund | 2,349,767 | 2.07 | 273.23 | 2,975,393 | 2025-12-14 20:43:52 | -21.03% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 11.07 | 10.89 | 11.38 | 6.25 | -1.59 |
| Diluted EPS (Rs.) | 11.01 | 10.84 | 11.36 | 6.24 | -1.59 |
| Cash EPS (Rs.) | 14.76 | 13.40 | 13.76 | 8.52 | 0.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 96.50 | 86.51 | 76.31 | 64.79 | 58.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 96.50 | 86.51 | 76.31 | 64.79 | 58.37 |
| Revenue From Operations / Share (Rs.) | 72.30 | 55.62 | 46.99 | 40.55 | 25.93 |
| PBDIT / Share (Rs.) | 20.62 | 17.18 | 14.21 | 11.03 | 5.37 |
| PBIT / Share (Rs.) | 16.92 | 14.66 | 11.82 | 8.75 | 3.57 |
| PBT / Share (Rs.) | 14.47 | 14.05 | 10.96 | 7.62 | -0.71 |
| Net Profit / Share (Rs.) | 11.07 | 10.88 | 11.37 | 6.24 | -1.19 |
| NP After MI And SOA / Share (Rs.) | 11.07 | 10.88 | 11.37 | 6.24 | -1.42 |
| PBDIT Margin (%) | 28.51 | 30.89 | 30.24 | 27.21 | 20.70 |
| PBIT Margin (%) | 23.40 | 26.36 | 25.15 | 21.58 | 13.75 |
| PBT Margin (%) | 20.00 | 25.25 | 23.31 | 18.79 | -2.74 |
| Net Profit Margin (%) | 15.30 | 19.56 | 24.18 | 15.38 | -4.57 |
| NP After MI And SOA Margin (%) | 15.30 | 19.56 | 24.18 | 15.38 | -5.49 |
| Return on Networth / Equity (%) | 11.46 | 12.57 | 14.89 | 9.63 | -2.43 |
| Return on Capital Employeed (%) | 12.27 | 13.25 | 12.67 | 10.06 | 4.43 |
| Return On Assets (%) | 7.07 | 8.81 | 10.92 | 6.58 | -1.60 |
| Long Term Debt / Equity (X) | 0.24 | 0.12 | 0.06 | 0.10 | 0.14 |
| Total Debt / Equity (X) | 0.26 | 0.13 | 0.07 | 0.11 | 0.15 |
| Asset Turnover Ratio (%) | 0.51 | 0.48 | 0.21 | 0.21 | 0.18 |
| Current Ratio (X) | 0.87 | 1.37 | 1.86 | 1.32 | 1.45 |
| Quick Ratio (X) | 0.81 | 1.30 | 1.79 | 1.24 | 1.38 |
| Inventory Turnover Ratio (X) | 74.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 13.55 | 9.18 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 10.15 | 7.45 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 86.45 | 90.82 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 89.85 | 92.55 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 12.15 | 27.89 | 16.45 | 10.61 | 2.89 |
| Interest Coverage Ratio (Post Tax) (X) | 7.97 | 18.66 | 14.16 | 7.09 | 1.66 |
| Enterprise Value (Cr.) | 108421.53 | 79785.85 | 41914.32 | 33863.11 | 20147.55 |
| EV / Net Operating Revenue (X) | 15.43 | 14.76 | 9.19 | 8.61 | 8.04 |
| EV / EBITDA (X) | 54.09 | 47.77 | 30.38 | 31.65 | 38.85 |
| MarketCap / Net Operating Revenue (X) | 15.17 | 14.75 | 9.38 | 8.56 | 7.95 |
| Retention Ratios (%) | 86.44 | 90.81 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 11.37 | 9.48 | 5.78 | 5.35 | 3.53 |
| Price / Net Operating Revenue (X) | 15.17 | 14.75 | 9.38 | 8.56 | 7.95 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.01 | -0.01 |
After reviewing the key financial ratios for Max Healthcare Institute Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.89 (Mar 24) to 11.07, marking an increase of 0.18.
- For Diluted EPS (Rs.), as of Mar 25, the value is 11.01. This value is within the healthy range. It has increased from 10.84 (Mar 24) to 11.01, marking an increase of 0.17.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.76. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 14.76, marking an increase of 1.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 96.50. It has increased from 86.51 (Mar 24) to 96.50, marking an increase of 9.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 96.50. It has increased from 86.51 (Mar 24) to 96.50, marking an increase of 9.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 72.30. It has increased from 55.62 (Mar 24) to 72.30, marking an increase of 16.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.62. This value is within the healthy range. It has increased from 17.18 (Mar 24) to 20.62, marking an increase of 3.44.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.92. This value is within the healthy range. It has increased from 14.66 (Mar 24) to 16.92, marking an increase of 2.26.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 14.05 (Mar 24) to 14.47, marking an increase of 0.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.88 (Mar 24) to 11.07, marking an increase of 0.19.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.88 (Mar 24) to 11.07, marking an increase of 0.19.
- For PBDIT Margin (%), as of Mar 25, the value is 28.51. This value is within the healthy range. It has decreased from 30.89 (Mar 24) to 28.51, marking a decrease of 2.38.
- For PBIT Margin (%), as of Mar 25, the value is 23.40. This value exceeds the healthy maximum of 20. It has decreased from 26.36 (Mar 24) to 23.40, marking a decrease of 2.96.
- For PBT Margin (%), as of Mar 25, the value is 20.00. This value is within the healthy range. It has decreased from 25.25 (Mar 24) to 20.00, marking a decrease of 5.25.
- For Net Profit Margin (%), as of Mar 25, the value is 15.30. This value exceeds the healthy maximum of 10. It has decreased from 19.56 (Mar 24) to 15.30, marking a decrease of 4.26.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.30. This value is within the healthy range. It has decreased from 19.56 (Mar 24) to 15.30, marking a decrease of 4.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.46. This value is below the healthy minimum of 15. It has decreased from 12.57 (Mar 24) to 11.46, marking a decrease of 1.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.27. This value is within the healthy range. It has decreased from 13.25 (Mar 24) to 12.27, marking a decrease of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has decreased from 8.81 (Mar 24) to 7.07, marking a decrease of 1.74.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.26. This value is within the healthy range. It has increased from 0.13 (Mar 24) to 0.26, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has increased from 0.48 (Mar 24) to 0.51, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 0.87. This value is below the healthy minimum of 1.5. It has decreased from 1.37 (Mar 24) to 0.87, marking a decrease of 0.50.
- For Quick Ratio (X), as of Mar 25, the value is 0.81. This value is below the healthy minimum of 1. It has decreased from 1.30 (Mar 24) to 0.81, marking a decrease of 0.49.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 74.28. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 74.28, marking an increase of 74.28.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.55. This value is below the healthy minimum of 20. It has increased from 9.18 (Mar 24) to 13.55, marking an increase of 4.37.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 10.15. This value is below the healthy minimum of 20. It has increased from 7.45 (Mar 24) to 10.15, marking an increase of 2.70.
- For Earning Retention Ratio (%), as of Mar 25, the value is 86.45. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 24) to 86.45, marking a decrease of 4.37.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 89.85. This value exceeds the healthy maximum of 70. It has decreased from 92.55 (Mar 24) to 89.85, marking a decrease of 2.70.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 12.15. This value is within the healthy range. It has decreased from 27.89 (Mar 24) to 12.15, marking a decrease of 15.74.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.97. This value is within the healthy range. It has decreased from 18.66 (Mar 24) to 7.97, marking a decrease of 10.69.
- For Enterprise Value (Cr.), as of Mar 25, the value is 108,421.53. It has increased from 79,785.85 (Mar 24) to 108,421.53, marking an increase of 28,635.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 15.43. This value exceeds the healthy maximum of 3. It has increased from 14.76 (Mar 24) to 15.43, marking an increase of 0.67.
- For EV / EBITDA (X), as of Mar 25, the value is 54.09. This value exceeds the healthy maximum of 15. It has increased from 47.77 (Mar 24) to 54.09, marking an increase of 6.32.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 15.17. This value exceeds the healthy maximum of 3. It has increased from 14.75 (Mar 24) to 15.17, marking an increase of 0.42.
- For Retention Ratios (%), as of Mar 25, the value is 86.44. This value exceeds the healthy maximum of 70. It has decreased from 90.81 (Mar 24) to 86.44, marking a decrease of 4.37.
- For Price / BV (X), as of Mar 25, the value is 11.37. This value exceeds the healthy maximum of 3. It has increased from 9.48 (Mar 24) to 11.37, marking an increase of 1.89.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 15.17. This value exceeds the healthy maximum of 3. It has increased from 14.75 (Mar 24) to 15.17, marking an increase of 0.42.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Max Healthcare Institute Ltd:
- Net Profit Margin: 15.3%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.27% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.46% (Industry Average ROE: 14.16%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 74 (Industry average Stock P/E: 78)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 15.3%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 401, 4th Floor, Man Excellenza, Mumbai Maharashtra 400056 | investors@maxhealthcare.com http://www.maxhealthcare.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Abhay Soi | Chairman & Managing Director |
| Mr. Pranav Amin | Independent Director |
| Mr. Michael Thomas Neeb | Independent Director |
| Mr. K Narasimha Murthy | Independent Director |
| Mr. Anil Kumar Bhatnagar | Non Executive Director |
| Mr. Narayan K Seshadri | Non Executive Director |
| Ms. Amrita Gangotra | Independent Woman Director |
| Mr. Mahendra Gumanmalji Lodha | Independent Director |
| Dr. Pranav C Mehta | Independent Director |
FAQ
What is the intrinsic value of Max Healthcare Institute Ltd?
Max Healthcare Institute Ltd's intrinsic value (as of 16 December 2025) is 775.48 which is 27.66% lower the current market price of 1,072.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,04,305 Cr. market cap, FY2025-2026 high/low of 1,314/940, reserves of ₹9,080 Cr, and liabilities of 16,281 Cr.
What is the Market Cap of Max Healthcare Institute Ltd?
The Market Cap of Max Healthcare Institute Ltd is 1,04,305 Cr..
What is the current Stock Price of Max Healthcare Institute Ltd as on 16 December 2025?
The current stock price of Max Healthcare Institute Ltd as on 16 December 2025 is 1,072.
What is the High / Low of Max Healthcare Institute Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Max Healthcare Institute Ltd stocks is 1,314/940.
What is the Stock P/E of Max Healthcare Institute Ltd?
The Stock P/E of Max Healthcare Institute Ltd is 74.0.
What is the Book Value of Max Healthcare Institute Ltd?
The Book Value of Max Healthcare Institute Ltd is 103.
What is the Dividend Yield of Max Healthcare Institute Ltd?
The Dividend Yield of Max Healthcare Institute Ltd is 0.14 %.
What is the ROCE of Max Healthcare Institute Ltd?
The ROCE of Max Healthcare Institute Ltd is 14.9 %.
What is the ROE of Max Healthcare Institute Ltd?
The ROE of Max Healthcare Institute Ltd is 12.7 %.
What is the Face Value of Max Healthcare Institute Ltd?
The Face Value of Max Healthcare Institute Ltd is 10.0.